Medscape is available in 5 Language Editions – Choose your Edition here.


Pediatric Allergic Rhinitis Medication

  • Author: Jack M Becker, MD; Chief Editor: Harumi Jyonouchi, MD  more...
Updated: May 04, 2016

Medication Summary

Many groups of medications are used for allergic rhinitis (AR), including antihistamines, corticosteroids, decongestants, saline, sodium cromolyn, and antileukotrienes. These can be further subdivided into intranasal and oral therapies. Intranasal administration has the advantage of directly affecting the site of action, and, in general, intranasal medications have fewer adverse effects and no systemic effects. The main advantage of oral therapy is ease of use. Some patients resist using intranasal medications.

Allergen-specific immunotherapy is an alternative form of therapy that has several advantages. Most importantly, it is the only form of therapy that can cure allergy symptoms. Allergen-specific immunotherapy must be customized to the patient's individual allergies and involves weekly injections of increasing concentrations of an allergen until the maintenance dose is reached and a monthly injection of the maintenance dose for several years. The process usually does not produce clinical results in the first 6 months but results are seen afterwards. The recommended course is usually 4-5 years. Allergen-specific immunotherapy has been demonstrated to be more cost effective and improves the patient's quality of life more efficiently than standard allergy medications.

Sublingual (SL) immunotherapy has been available in other countries of the world.[11] In this form of therapy, small amounts of the allergen are placed under the tongue on a daily basis. The 2 main advantages are that no injections are necessary and treatment can be administered at home. In spite of the safety record of sublingual therapy, which has very few serious reactions, the FDA recommendations are that the first dose be given in a physician's office and an epinephrine autoinjector is to be prescribed.

In April 2014, the FDA approved 3 SL tablets. Two are for grass allergies and the third is for ragweed. Oralair consists of 5 calibrated grass pollen extracts (Oralair). It contains Perennial Ryegrass (Lolium perenne), Kentucky bluegrass (Poa pratensis), Timothy grass (Phleum pratense), Orchard grass (Dactylis glomerata), and Sweet Vernal grass (Anthoxanthum odoratum).[13] The Oralair SL tablet needs to be initiated 4 months prior to the season for the specific allergen. It is approved for adults and children aged 10-65 years.

The second SL immunotherapy for grass is only one type of grass. Timothy grass (Grastek) was also approved in April 2014. It should be initiated at least 12 weeks before the start of the grass pollen season.[14] Efficacy and safety in North America was established in a large study (n=1500) of adults and children aged 5-65 years. Results showed a 23% improvement of symptoms in the entire grass pollen season.[15] Timothy grass cross-reacts with the following grasses, including sweet vernal, orchard (also known as cocksfoot), perennial rye, Kentucky blue (also known as June grass), meadow fescue, and redtop. This high cross-reactivity allows for Grastek to be effective for a patient with grass allergies.

The third one is Ragwiteck. Like the other 2, it needs to be started prior to the onset of the season. It is a short ragweed extract for adults aged 18-65 years.

Saline nasal irrigation is effective in approximately 50% of patients with allergic rhinitis. Irrigation assists the body's natural function of rinsing allergens out of nasal passages. Tap water cannot be used because it is hypotonic and causes edema, leading to greater congestion.


Antihistamines, 2nd Generation

Class Summary

Antihistamines are classified in several ways, including sedating and nonsedating, newer and older, and first- and second-generation antihistamines (most widely accepted classification). First-generation antihistamines are primarily over-the-counter OTC) and are included in many combination products for cough, colds, and allergies. These include brompheniramine, chlorpheniramine (Chlor-Trimeton), and diphenhydramine (Benadryl). Some 2nd generation antihistamines, such as fexofenadine (Allegra), loratadine (Claritin), and cetirizine (Zyrtec) are now available OTC without a prescription. Second-generation antihistamines include desloratadine (Clarinex), and levocetirizine dihydrochloride (XYZAL), which require a prescription.

Cetirizine (Zyrtec, Zyrtec Allergy, Children's Zyrtec Allergy)


Low-sedating second-generation medication with fewer adverse effects than first-generation medications. Selectively inhibits peripheral histamine H1 receptors. Available as syr (5 mg/5 mL) and 5- or 10-mg tab.

Levocetirizine (Xyzal)


Histamine H1-receptor antagonist. Active enantiomer of cetirizine. Peak plasma levels are reached within 1 h, and half-life is about 8 h. Available as a 5-mg breakable (scored) tab. Indicated for seasonal and perennial AR

Loratadine (Claritin)


Nonsedating second-generation antihistamine. Fewer adverse effects than with first-generation medications. Selectively inhibits peripheral histamine H1 receptors. Available as tab, disintegrating tab (Reditab), syr (5 mg/5 mL), or combined with pseudoephedrine in 12- or 24-h preparations. The only one that is presently available without a prescription

Desloratadine (Clarinex, Clarinex RediTabs)


Nonsedating second-generation antihistamine. Fewer adverse effects than with first-generation antihistamines. Selectively inhibits peripheral histamine H1 receptors. Relieves nasal congestion and systemic effects of seasonal allergies. Long-acting tricyclic histamine antagonist selective for H1-receptor. Major metabolite of loratadine, which, after ingestion, is extensively metabolized to active metabolite 3-hydroxydesloratadine. Available as tabs, syr (0.5 mg/mL), or PO disintegrating Reditabs (2.5 and 5 mg).

Fexofenadine (Allegra, Allegra Allergy 12 Hour, Allegra Allergy 24 Hour, Children's Allegra Allergy)


Nonsedating second-generation medication with fewer adverse effects than first-generation medications. Competes with histamine for H1 receptors in GI tract, blood vessels, and respiratory tract, reducing hypersensitivity reactions. Available OTC in qd and bid preparations. Also OTC available combined with pseudoephedrine.


Intranasal Antihistamines

Class Summary

These agents are an alternative to oral antihistamines to treat allergic rhinitis. Currently, azelastine and olopatadine are the only agents available in the United States.

Azelastine (Astelin Nasal Spray, Astepro)


An effective antihistamine delivered via the intranasal route. Mechanism is similar to PO antihistamines. Systemic absorption occurs and may cause sedation, headache, and nasal burning.

Olopatadine intranasal (Patanase)


Intranasal antihistamine indicated for seasonal allergic rhinitis. Available as 6% intranasal solution (delivers 665 mcg/spray).


Corticosteroids, Intranasal

Class Summary

This class of medications is most effective. Intranasal corticosteroids are potent anti-inflammatory agents shown to decrease allergic rhinitis symptoms in more than 90% of patients. Presently, 9 medications are available in this class, and all are essentially equivalent in efficacy, although few head-to-head studies have been performed. Mometasone (Nasonex) and fluticasone furoate (Veramyst) have been demonstrated to have a somewhat faster onset of action; however, after one week, no difference is found between medications. Most can be used on a once-daily basis, and all have a similar safety profile. Nasonex is the only medication that did not show an effect on growth at one year. Veramyst did not show a growth effect in a 2-week study that is designed to evaluate for growth affects.

There are 2 nasal inhalers, Qnasl and Zetonna. They are a spray form and allow for better nasal deposition for some patients who like a spray-type inhaler. They have shown to help decrease ocular symptoms. In the spring of 2014, Nasacort (triamcinolone) was approved as an over-the-counter medication.

Beclomethasone, intranasal (Beconase AQ, QNASL)


Corticosteroid with potent anti-inflammatory properties. Elicits effects on various cells, including mast cells and eosinophils. It also elicits effects on inflammatory mediators (eg, histamine, eicosanoids, leukotrienes, cytokines). Available in solution or suspension forms and delivered as a metered-dose nasal sprays. Beconase AQ is approved for children aged 6 y or older. QNASL is indicated for children aged 4 y or older.

Budesonide intranasal (Rhinocort Aqua)


May decrease number and activity of inflammatory cells, resulting in decreased nasal inflammation.

Ciclesonide intranasal (Omnaris, Zetonna)


Corticosteroid nasal spray indicated for AR. Prodrug that is enzymatically hydrolyzed to pharmacologic active metabolite C21-desisobutyryl-ciclesonide following intranasal application. Corticosteroids have a wide range of effects on multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (eg, histamines, eicosanoids, leukotrienes, cytokines) involved in allergic inflammation. Each spray delivers 50 mcg.

Flunisolide intranasal (Nasarel)


May decrease number and activity of inflammatory cells, resulting in decreased nasal inflammation.

Fluticasone intranasal (Flonase, Veramyst)


May decrease number and activity of inflammatory cells, resulting in decreased nasal inflammation.

Mometasone, intranasal (Nasonex)


May decrease number and activity of inflammatory cells, resulting in decreased nasal inflammation. Demonstrated no mineralocorticoid, androgenic, antiandrogenic, or estrogenic activity in preclinical trials. Decreases rhinovirus-induced up-regulation in respiratory epithelial cells and modulate pretranscriptional mechanisms. Reduces intraepithelial eosinophilia and inflammatory cell infiltration (eg, eosinophils, lymphocytes, monocytes, neutrophils, plasma cells).

Triamcinolone, intranasal (Nasacort AQ)


May decrease number and activity of inflammatory cells, resulting in decreased nasal inflammation.


Antihistamine/Corticosteroid, Intranasal

Class Summary

Combination products are emerging on the market for patients who require an intranasal antihistamine and corticosteroids.

Azelastine/fluticasone intranasal (Dymista)


This combination product elicits histamine H1-receptor antagonist activity and anti-inflammatory effects. It is indicated for seasonal allergic rhinitis in adults and children aged 12 years or older.


Intranasal decongestants

Class Summary

Decongestants are effective for short-term symptom control. They decrease nasal discharge and congestion and are available without a prescription. The 2 medications in this group are oxymetazoline hydrochloride (Afrin) and ipratropium bromide (Atrovent). Oxymetazoline hydrochloride is effective in shrinking nasal membranes and is not recommended for long-term use. Use of oxymetazoline hydrochloride for more than 7-10 days can cause rebound congestion. When used for >4-6 days nasal vasoconstrictive medications, that are used topically, can cause rhinitis medicamentosa, a condition characterized by nasal congestion in the absence of rhinorrhea or sneezing. Ipratropium bromide can be used for a prolonged period of time.

Ipratropium intranasal (Atrovent Nasal Spray)


Anticholinergic used for reducing rhinorrhea in patients with AR or vasomotor rhinitis. An excellent medication for decreasing rhinitis. Does not cause rebound congestion and lasts for 12 hours. Does not shrink the nasal mucosa, but inhibits secretion that causes rhinitis. Used alone or in conjunction with other medications.

Oxymetazoline (Afrin 12 Hour, Afrin Sinus, Mucinex Nasal Spray Full Force, Sinus Nasal Spray, Dristan Spray)


A representative topical decongestant applied directly to mucous membranes, where it stimulates alpha-adrenergic receptors and causes vasoconstriction. Decongestion occurs without drastic changes in BP, vascular redistribution, and cardiac stimulation. Use not recommended for >3 days.


Intranasal mast cell stabilizers

Class Summary

These are effective therapy for AR in approximately 70-80% of patients. They produce mast cell stabilization and antiallergic effects by inhibiting mast cell degranulation. They have no direct anti-inflammatory or antihistaminic effects and minimal bronchodilator effects. They are effective for prophylaxis. They also clean out antigens mechanically, similar to saline. These products are now available over the counter.

Cromolyn sodium, intranasal (NasalCrom)


Used on a daily basis for seasonal or perennial AR. Significant effect may not be seen for 4-7 d. Administer just before exposure in patients with isolated and predictable periods of exposure (eg, animal allergy, occupational allergy). Generally less effective than nasal corticosteroids. Protective effect lasts 4-8 h; thus, frequent dosing is necessary. If desired, may be used with other medicines, including other allergy medicines.


Leukotriene Receptor Antagonists

Class Summary

Montelukast has been approved as monotherapy for allergic rhinitis. It has been shown to be most effective in patients in whom significant congestion is a primary complaint. It has also been shown to work as adjunctive therapy with present second-generation antihistamines to provide greater relief of symptoms than antihistamines alone. It is beneficial in patients with symptoms in whom present antihistamines are not adequate. A study has shown a combination with cetirizine is as effective as an intranasal corticosteroid. Antileukotriene can also be added to the treatment plan in patients receiving antihistamines and intranasal therapy.

Montelukast (Singulair)


Inhibits airway cysteinyl leukotriene receptors. Because these receptors are found throughout the airway, the medication can mediate the effect in the upper and lower airway.


Allergy Extracts

Class Summary

Immunotherapy with daily sublingual (SL) tablets may be able to replace weekly injections in some individuals, depending on the offending allergens. SL tablets must be initiated 4 months before the allergen season that is being treated.

Grass pollens allergen extract (Oralair)


SL immunotherapy is indicated for grass pollen–induced allergic rhinitis (with or without conjunctivitis) confirmed by positive skin test or in vitro testing for grass pollen–specific immunoglobulin E antibodies for any of the 5 grass species contained in the product. It consists of 5 purified and calibrated pollen extracts: Perennial Ryegrass (Lolium perennePoa pratensis), Timothy grass (Phleum pretense), Orchard grass (Dactylis glomerata), and Sweet Vernal grass (Anthoxanthum odoratum). It is approved for adults and children aged 10-65 years.

Timothy grass pollen allergen extract (Grastek)


SL immunotherapy is indicated for allergic rhinitis (with or without conjunctivitis) confirmed by positive skin test or in vitro testing for Timothy grass pollen-specific IgE antibodies. Is approved for adults and children aged 5-65 years.

Contributor Information and Disclosures

Jack M Becker, MD Clinical Associate Professor of Pediatrics, Drexel University College of Medicine

Jack M Becker, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American College of Allergy, Asthma and Immunology

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: TEVA Pharmaceuticals.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Harumi Jyonouchi, MD Faculty, Division of Allergy/Immunology and Infectious Diseases, Department of Pediatrics, Saint Peter's University Hospital

Harumi Jyonouchi, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association of Immunologists, American Medical Association, Clinical Immunology Society, New York Academy of Sciences, Society for Experimental Biology and Medicine, Society for Pediatric Research, Society for Mucosal Immunology

Disclosure: Nothing to disclose.

Additional Contributors

C Lucy Park, MD Chief, Division of Allergy, Immunology, and Pulmonology, Associate Professor, Department of Pediatrics, University of Illinois at Chicago College of Medicine

C Lucy Park, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, Chicago Medical Society, American Medical Association, Clinical Immunology Society, Illinois State Medical Society

Disclosure: Nothing to disclose.


John Wilson Georgitis, MD Consulting Staff, Lafayette Allergy Services

John Wilson Georgitis, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association for the Advancement of Science, American College of Chest Physicians, American Lung Association, American Medical Writers Association, and American Thoracic Society

Disclosure: Nothing to disclose.

  1. Hand L. First-year allergen exposures may reduce later risks. Medscape Medical News. June 11, 2014. [Full Text].

  2. Lynch SV, Wood RA, Boushey H, Bacharier LB, Bloomberg GR, Kattan M, et al. Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children. J Allergy Clin Immunol. 2014 May 28. [Medline].

  3. Meltzer EO. Productivity costs of antihistamines in the workplace. Occup Health Saf. 1996 Aug. 65(8):46-50. [Medline].

  4. [Guideline] World Health Organization (WHO). Allergic rhinitis and its impact on asthma. 2008. [Full Text].

  5. Crystal-Peters J, Neslusan C, Crown WH, Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol. 2002 Jan. 109(1):57-62. [Medline].

  6. Gendo K, Larson EB. Evidence-based diagnostic strategies for evaluating suspected allergic rhinitis. Ann Intern Med. 2004 Feb 17. 140(4):278-89. [Medline].

  7. Malone DC, Lawson KA, Smith DH, Arrighi HM, Battista C. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol. 1997 Jan. 99(1 Pt 1):22-7. [Medline].

  8. Herr M, Clarisse B, Nikasinovic L, et al. Does allergic rhinitis exist in infancy? Findings from the PARIS birth cohort. Allergy. 2011 Feb. 66(2):214-21. [Medline].

  9. Hatzler L, Panetta V, Lau S, Wagner P, Bergmann RL, Illi S, et al. Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever. J Allergy Clin Immunol. 2012 Jul 25. [Medline].

  10. Söderström L, Lilja G, Borres MP, Nilsson C. An explorative study of low levels of allergen-specific IgE and clinical allergy symptoms during early childhood. Allergy. 2011 Aug. 66(8):1058-64. [Medline].

  11. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006 May. 117(5):1021-35. [Medline].

  12. Compalati E, Penagos M, Tarantini F, Passalacqua G, Canonica GW. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol. 2009 Jan. 102(1):22-8. [Medline].

  13. FDA OKs Oralair, First US Sublingual Allergy Immunotherapy. Medscape. Available at Accessed: April 4, 2014.

  14. Grastek [package insert]. Whitehouse Station, NJ: Merck & Co, Inc. April 2014. Available at [Full Text].

  15. Maloney J, Bernstein DI, Nelson H, Creticos P, Hébert J, Noonan M, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014 Feb. 112(2):146-153.e2. [Medline].

  16. Aaronson DW. Side effects of rhinitis medications. J Allergy Clin Immunol. 1998 Feb. 101(2 Pt 2):S379-82. [Medline].

  17. Allergies in America. Allergies in America Executive Summary. myallergiesinamerica. Available at Accessed: June 2007.

  18. Brooks M. FDA OKs carbinoxamine ER for allergic rhinitis in children. Medscape Medical News. April 3, 2013. Available at Accessed: April 8, 2013.

  19. Busse W. Allergic rhinitis: charting a course for the 21st century. J Respir Dis. 1998. 19:S1-64.

  20. Day J. Pros and cons of the use of antihistamines in managing allergic rhinitis. J Allergy Clin Immunol. 1999 Mar. 103(3 Pt 2):S395-9. [Medline].

  21. Day JH, Briscoe M, Widlitz MD. Cetirizine, loratadine, or placebo in subjects with seasonal allergic rhinitis: effects after controlled ragweed pollen challenge in an environmental exposure unit. J Allergy Clin Immunol. 1998 May. 101(5):638-45. [Medline].

  22. Delafuente JC, Davis TA, Davis JA. Pharmacotherapy of allergic rhinitis. Clin Pharm. 1989 Jul. 8(7):474-85. [Medline].

  23. FDA approves Tris Pharma’s new drug application for Karbinal ER (carbinoxamine maleate) extended-release oral suspension [press release]. April 3, 2013. Available at Accessed: April 8, 2013.

  24. Hemp P. Presenteeism: at work--but out of it. Harv Bus Rev. 2004 Oct. 82(10):49-58, 155. [Medline].

  25. Hussain I, Kline JN. DNA, the immune system, and atopic disease. J Investig Dermatol Symp Proc. 2004 Jan. 9(1):23-8. [Medline].

  26. LaForce C. Use of nasal steroids in managing allergic rhinitis. J Allergy Clin Immunol. 1999 Mar. 103(3 Pt 2):S388-94. [Medline].

  27. Lange B, Lukat KF, Rettig K, Holtappels G, Bachert C. Efficacy, cost-effectiveness, and tolerability of mometasone furoate, levocabastine, and disodium cromoglycate nasal sprays in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2005 Sep. 95(3):272-82. [Medline].

  28. Ledford DK, Lockey RF. Allergic rhinitis: understanding the process. J Respir Dis. 1998. 19(7):576-84.

  29. Middleton E, Reed C, Ellis E. Allergic and non-allergic rhinitis. Allergy: Principles and Practice. 5th ed. Mosby-Year Book; 1998. Vol 2: Chapter 70.

  30. Naclerio R, Solomon W. Rhinitis and inhalant allergens. JAMA. 1997 Dec 10. 278(22):1842-8. [Medline].

  31. Plevkova J, Brozmanova M, Pecova R, Tatar M. Effects of intranasal histamine on the cough reflex in subjects with allergic rhinitis. J Physiol Pharmacol. 2005 Sep. 56 Suppl 4:185-95. [Medline].

  32. Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc. 1994 Jan-Feb. 15(1):21-5. [Medline].

  33. Spector S. Pathophysiology and pharmacotherapy of allergic rhinitis. Foreword. J Allergy Clin Immunol. 1999 Mar. 103(3 Pt 2):S377. [Medline].

  34. Sublett JL. The environment and risk factors for atopy. Curr Allergy Asthma Rep. 2005 Nov. 5(6):445-50. [Medline].

  35. Wahn U, Klimek L, Ploszczuk A, Adelt T, Sandner B, Trebas-Pietras E, et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: A double-blind, placebo-controlled study. J Allergy Clin Immunol. 2012 Aug 29. [Medline].

  36. Wahn U, Tabar A, Kuna P, et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009 Jan. 123(1):160-166.e3. [Medline].

  37. Wheeler PW, Wheeler SF. Vasomotor rhinitis. Am Fam Physician. 2005 Sep 15. 72(6):1057-62. [Medline].

Photo demonstrates the allergic salute, which is the action performed when a patient rubs the nose using a motion across the nose.
Photo demonstrates allergic shiners. Note the periorbital edema and bluish discoloration seen in allergic rhinitis and sinusitis.
Impact of nasal allergies.
How patient feel when they have allergy symptoms.
Nasal symptoms and affect on work performance.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.